|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer显示文摘DNA 修理能力(DRC ) 向基于铂的化疗与癌症房间的敏感被相关。我们假设那在 DNA 的基因多型性修理基因 XPA (干皮病 pigmentosum 组 A )和 XPG (干皮病 pigmentosum 组 G )( ERCC5 ,切除修理跨互补的组 5 ),它在 DNA 修理效率导致内部个人的差别,可以在先进非小的房间肺癌症( NSCLC )预言临床的反应到铂代理人病人。在这研究,我们发现 XPA A23G 多型性的 A G 变化显著地增加了反应到基于铂的化疗。在 XPG His46His 的多型性与减少的治疗回答被联系,但是不是统计上重要的。 | Jifeng Feng Xinchen Sun Ning Sun Shukui Qin Fan Li Hongyan Cheng Baoan Chen YuanDong Cao Jun Ma Lu Cheng Zuhong Lu Jiazhong Ji Yingfeng Zhou | 2009 | Acta Biochimica et Biophysica Sinica2009，41，5： | 8 |
| 2 | Simultaneous analysis of 11 main active components in C irsium setosum based on HPLC ‐ ESI ‐ MS / MS and combined with statistical methods显示文摘 | Qian Sun Lu Chang Yanping Ren Liang Cao Yingguang Sun Yingfeng Du Xiaowei Shi Qiao Wang Lantong Zhang | 2012 | J. Sep. Science2012，，21： | 1 |
| 3 | Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients显示文摘 | Xinchen Sun Fan Li Ning Sun Qin Shukui Chen Baoan Feng Jifeng Cheng Lu Lu Zuhong Cheng Hongyan Cao YuanDong Ji Jiazhong Zhou Yingfeng | 2008 | Lung Cancer2008，，2： | 1 |
| 4 | Bladder microenvironment actuated proteomotors with ammonia amplification for enhanced cancer treatment显示文摘Enzyme-driven micro/nanomotors consuming in situ chemical fuels have attracted lots of attention for biomedical applications.However,motor systems composed by organism-derived organics that maximize the therapeutic efficacy of enzymatic products remain challenging.Herein,swimming proteomotors based on biocompatible urease and human serum albumin are constructed for enhanced antitumor therapy via active motion and ammonia amplification.By decomposing urea into carbon dioxide and ammonia,the designed proteomotors are endowed with self-propulsive capability,which leads to improved internalization and enhanced penetration in vitro.As a glutamine synthetase inhibitor,the loaded L-methionine sulfoximine further prevents the conversion of toxic ammonia into non-toxic glutamine in both tumor and stromal cells,resulting in local ammonia amplification.After intravesical instillation,the proteomotors achieve longer bladder retention and thus significantly inhibit the growth of orthotopic bladder tumor in vivo without adverse effects.We envision that the as-developed swimming proteomotors with amplification of the product toxicity may be a potential platform for active cancer treatment. | Hao Tian Juanfeng Ou Yong Wang Jia Sun Junbin Gao Yicheng Ye Ruotian Zhang Bin Chen Fei Wang Weichang Huang Huaan Li Lu Liu Chuxiao Shao Zhili Xu Fei Peng Yingfeng Tu | 2023 | Acta Pharmaceutica Sinica B2023，13，9： | 0 |
| 5 | Seizures in posterior reversible encephalopathy syndrome:blood pressure management in normotensive patients显示文摘Posterior reversible encephalopathy syndrome(PRES)is a rare clinical disease that refers to the subcortical vasogenic edema involving bilateral parieto-occipital regions,with a usually reversible syndrome when causes are eliminated or controlled.Hypertension or blood pressure fluctuations are most common causes of PRES,but other contributors like chemotherapy and autoimmune disorders have also been reported.PRES has rapid onset of symptoms.Therefore,it is of major importance to determine whether blood pressure management plays an important role in prognosis.We presented two PRES patients who developed non-convulsive seizure but had normal baseline blood pressure at the time of presence of cause.The diagnosis of PRES was made by neurologists.The patients had no history of seizure or hypertension,but during the disease course they presented with temporal elevation of blood pressure with different durations.The second patients without instant blood pressure control developed residual symptoms of seizure at 90-and 120-day follow-up.Although the exact pathophysiology of PRES remains to be fully understood,primary and secondary prolonged blood pressure fluctuations may be associated with the prognosis of this syndrome.Early blood pressure management would be critical to favorable outcome. | Lu Lu Weixi Xiong Yingying Zhang Yingfeng Xiao Dong Zhou | 2021 | Acta Epileptologica2021，3，1： | 0 |
| 6 | Immunomodulatory and Antiviral Therapy Improved Functional Cure Rate in CHB Patients with High HBsAg Level Experienced NA显示文摘Background and Aims:A functional cure,or hepatitis B virus(HBV)surface antigen(HBsAg)loss,is difficult to achieve in patients with hepatitis B virus e antigen(HBeAg)-positive chronic hepatitis B.The HBV vaccine and granulocyte-macrophage colony-stimulating factor(GM-CSF)have been reported to help reduce HBsAg levels and promote HBsAg loss.In this prospective randomized trial,we evaluated HBsAg loss in patients receiving pegylated interferon α2b(PEGIFN-α2b)and tenofovir disoproxil fumarate(TDF),with and without GM-CSF and HBV vaccination.Methods:A total of 287 patients with HBeAg positive chronic hepati-tis B and seroconversion after nucleot(s)ide analog treat-ment were assigned randomly to three treatment groups for 48 weeks,TDF alone(control),PEGIFN-α2b+TDF,and PEGIFN-α2b+TDF+GM-CSF+HBV vaccine.The prima-ry endpoints were the proportions of patients with HBsAg loss and seroconversion at 48 and 72 weeks.Resu/ts:The cumulative HBsAg loss rates in the control,PEGIFN-α2b+TDF,and PEGIFN-α2b+TDF+GM-CSF+HBV vaccine groups at week 48 were 0.0%,28.3%,and 41.1%,respec-tively.The cumulative HBsAg seroconversion rates in these groups at week 48 were 0.0%,21.7%,and 33.9%,respec-tively.Multivariate regression analysis showed that GM-CSF use plus HBV vaccination was significantly associated with HBsAg loss(p=0.017)and seroconversion(p=0.030).Con-clusions:In patients with HBeAg-positive chronic hepatitis B and seroconversion after nucleot(s)ide analog treatment,immunomodulatory/antiviral treatment regimens effective-ly improved HBsAg loss,and the regimen including GM-CSF and HBV vaccination was most effective. | Hongyu Jia Guodong Yu Jiong Yu Xiaoli Zhang Lisha Yang Bin Wang Jiming Zhang Lang Bai Xinxin Zhang Kai Wang Ping Zhao Dongliang Yang Yingren Zhao Yanyan Yu Yimin Zhang Jueqing Gu Chanyuan Ye Huan Cai Yingfeng Lu Dairong Xiang Liang Yu Jiangshan Lian Jianhua Hu Shanyan Zhang Ciliang Jin Yida Yang | 2023 | Journal of Clinical and Translational Hepatology2023，11，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员